Deals
Lilly Bets on Kelonia's In Vivo CAR-T
Lilly paid an undisclosed sum upfront for Kelonia Therapeutics on Monday, placing a large bet on in vivo CAR-T as its next platform priority.
Latest — Page 17
FDA
Novo Targets FDA Filing for Etavopivat After 27% VOC Reduction
Etavopivat cut vaso-occlusive crisis rates by 27% in a 385-patient phase 3 trial, and Novo Nordisk is now targeting an FDA submission in the second half of…
Deals
Kailera Raises $625M in Record Biotech IPO on Nasdaq
Kailera Therapeutics raised $625 million Friday in a record-setting biotech IPO on the Nasdaq.
Legal
OCC Hits Federal Savings Bank With Consent Order for Deceptive VA Loan Ads
The OCC issued a consent order against The Federal Savings Bank of Chicago this month, alleging deceptive acts or practices in the bank's advertising to…
Legal
FinCEN Filed NPRM Offering 10-30% Cut to Financial Crime Whistleblowers
FinCEN published a Notice of Proposed Rulemaking under 31 U.S.C. § 5323 that would pay whistleblowers 10-30% of monetary sanctions collected in cases…
Deals
Kraken Paid $550M for Bitnomial's Triple CFTC License Stack
Kraken paid up to $550 million for Bitnomial, a derivatives firm, in a deal that closes by June.
FDA
RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25
Revolution Medicines' pan-RAS inhibitor delivered a landmark Phase 3 survival readout at AACR25 that doubled survival, setting off what the oncology field…
Deals
UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy
UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.
SEC
OCC Clears JPMorgan's $250M Trade Surveillance Order After 2 Years
$348.2 million later, the OCC decided JPMorgan Chase has done enough.
Deals
Bought Comerica. Now Fifth Third Converts 500,000 Customers by Labor Day
Fifth Third bought Comerica in February, folding in about $294 billion in assets and roughly 500,000 retail customers.
FDA
Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3
Merck's MK-2010 posted a 55% unconfirmed overall response rate among 11 previously untreated PD-L1-positive non-small cell lung cancer patients, the first…
Deals
Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record
Kailera Therapeutics priced just under 40 million shares at $16 apiece Friday, pulling in $625 million on its Nasdaq debut under KLRA.
Deals
Topped $30B: Revolution Medicines Buyout Climbs on Cancer Win
Revolution Medicines had a rumored $30 billion buyout offer on the table in January.
Legal
Revived: $176.5M Patent Verdict Leaves Lilly to Evaluate Options
The Court of Appeals for the Federal Circuit on Thursday reinstated the $176.5 million verdict that Teva won in 2022, reviving its claim that Eli Lilly's…
Deals
Kailera Prices $625M IPO, Largest Biotech Since Moderna
Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings…
